The Global Pharmacovigilance Landscape Considerations Beyond the US and the EU

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

whitePaper | March 10, 2023

This pharma messaging guidebook features 20 proven cognitive science techniques that can be used to optimize pharmaceutical claims and messages.